Merck and Pfizer’s Steglatro meets primary goal in VERTIS CV trial
Merck (MSD) and Pfizer have reported that the Phase III VERTIS cardiovascular (CV) outcomes clinical trial of Steglatro (ertugliflozin) met its primary endpoint in patients with type 2 diabetes and atherosclerotic CV disease.
AstraZeneca to stop DAPA-CKD trial of Farxiga early
AstraZeneca is set to stop the Phase III DAPA-CKD clinical trial of Farxiga (dapagliflozin) early after the drug showed encouraging efficacy profile.
Isturisa (osilodrostat) for the Treatment of Cushing’s Disease
Isturisa® (osilodrostat) is the first cortisol synthesis inhibitor indicated for the treatment of Cushing's disease in adult patients, who are ineligible or failed pituitary surgery.
MiNA Therapeutics starts clinical trial of MTL-CEBPA to treat solid tumours
UK-based MiNA Therapeutics has started the Phase I clinical trial (TIMEPOINT) of MTL-CEBPA for the treatment of patients suffering with advanced solid tumours.
Arrowhead doses first patient in Phase I/II trial of ARO-HSD
US-based biopharmaceutical firm Arrowhead Pharmaceuticals has started dosing subjects in a Phase I/II clinical trial (AROHSD1001) of ARO-HSD for the treatment of patients suffering from alcohol and non-alcohol related liver diseases, such as nonalcoholic steatohepatitis (NASH).
NGM Bio’s aldafermin shows favourable profile in Phase II NASH study
NGM Biopharmaceuticals has reported positive data from the fourth cohort of a Phase II clinical trial of aldafermin in non-alcoholic steatohepatitis (NASH) patients.
Alnylam closes enrolment in Phase III trial of vutrisiran
Alnylam Pharmaceuticals has completed patient enrolment in the Phase III HELIOS-A clinical trial of vutrisiran for the treatment of hereditary transthyretin (hATTR) amyloidosis.
Rybelsus (Semaglutide) for the Treatment of Type 2 Diabetes
Rybelsus® (semaglutide) is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes in adult patients.
Boehringer Ingelheim reports positive CV data of linagliptin
Boehringer Ingelheim has reported positive data from a subgroup analysis of the CARMELINA clinical trial of linagliptin in type 2 diabetes patients.